RAPT beat EPS expectations by 31.56%
Nov 07, 2025, 11:35 PM
0.00%
What does RAPT do
Rapt Therapeutics, based in South San Francisco, specializes in developing oral small molecule therapies for oncology and inflammatory diseases, with key candidates targeting CCR4. The company went public on October 31, 2019, and employs 126 people.
RAPT Therapeutics (RAPT) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, RAPT Therapeutics's actual EPS was -$0.65, beating the estimate of -$0.95 per share, resulting in a 31.56% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.